

# Analysis of Variance

## Presentation Schedules

Member 1 Name/ UNI	Member 2 Name/ UNI	Member 3 Name/ UNI	Member 4 Name/ UNI	Member 5 Name/ UNI	Date
Jingya Xu/jx2197	Yicheng Liu/yl3072	Jiawen Wang/jw3151			10/3/2014
Nan Jiang/nj2291	Junrui Cao/jc4131	Boyi Lu/bl2501	Jing Zhang/jz2548	Meichen Zhou/mz2428	10/3/2014
Michael Piccirilli / mrp2181	Yifan Guo / yg2347	Jingnan Li / jl4174	Ruixin Tan / rt2521	Yu-Hua Cheng / yc2911	10/10/2014
Fang Guo / fg2332	Biyang Jiang / bj2312	Guangyu Sun / gs2741	Haokun Zhang / hz2318	Yi Zheng / yz2617	10/10/2014
Danyan Zhao / dz2263	Liyang Mai / lm2997	Wenyuan Liu / wl2458	Zhicheng Zhang / zz2296	Yuetong Pan / yp2349	10/10/2014
Dongying Song / ds3268	Jia Jia / jj2685	Meng Chen / mc3823	Danni Chen / dc2960	Yilu Wen / yw2585	10/10/2014
Donghuang Chen/ dc2959	Yunting Shi/ ys2748	Linyi Dong/ ld2585	Xiaohuan Li/ xl2411	Yingfei Jiang /yj2307	10/17/2014
Jialin Li / jl4176	Xiaogan Mao / xm2155	Fan Heng / fh2294	Lu Han / lh2659	Zhe Zheng / zz2297	10/17/2014
Qiumeng Duan / qd2122	Ruibo Li / rl2692	Qun Ren / qr2133	Zhiyuan Lai / zl2366	Zhehan Zhu / zz2295	10/17/2014
Zhou Lu/ zl2363	Xinxiang Zhou/xz2366	Zheng Li/ zl2362	Shaohui Wang/sw2855	Xinyue Li/xl2408	10/17/2014
Mengni Sun/ms4783	Yicheng Lu/yl3071	Zhao Hu/zh2210	Yucen Han/yh2645	Jiong Chen/jc4133	10/17/2014
Zifan Lin / zl2364	Yixuan Li / yl3067	Xun Wang / xw2314	Yuanqi Li / yl3073	Lisha Tan / lt2512	10/24/2014
Mingqian Guo / mg3418	Xueying Mei / xm2156	Yan Wu / yw2592	Jingdan Liu / jl4177	Jiayi Wu / jw3150	10/24/2014
Zhaofeng Tang/ zt2173	Yingyi Li/ yl3069	Xiaoyao Yang/ xy2231	Shilun Qu/ sq2155	Jundong He/ jh3425	10/24/2014
Jiacheng Xie/ jx2220	Xin Liu / xl2409	Ruqi Yi / ry2257	Zhuoqun Yu / zy2190	Linglin He / lh2660	10/24/2014
Jiun Kim / jk3662	Huei-Chung Huang /hh2553	Wonik Jang / wj2216			10/24/2014
Hang Gao / hg2361	Yuhang Xu / yx2253				10/24/2014

# ANALYSIS OF VARIANCE

Examples: Data on blood pressure reductions for patients receiving 3 different drugs.

- Six patients randomized to each drug
- Sitting diastolic pressure measured before randomization (baseline) and after 4 weeks of treatment.

Drug 1: 10, 11, 15, 11, 12, 37

Drug 2: 8, 7, 8, 10, 12, 11

Drug 3: 7, 9, 11, 9, 4, 2

# One-Way ANOVA

- **Data:**  $Y_{ij}, i = 1, \dots, I; j = 1, \dots, n_i$

$Y_{ij}$  is distributed normally with mean  $\mu_i$ , and constant variance

Wish to test:

$$H_0 : \mu_1 = \dots = \mu_I$$

against the alternative  $H_1 : \mu_i \neq \mu_j$  for at least one pair  $(i, j), i \neq j$ .

One approach to model the data is to use the following formulation,

$$Y_{ij} = \mu_i + \epsilon_{ij}$$

Under the normality assumption, the maximum likelihood estimators of the means are given by

$$\hat{\mu}_i = \frac{\sum_j Y_{ij}}{n_i}$$

which also correspond to the OLS estimators obtained by minimizing

$$\sum_{ij} (Y_{ij} - \mu_i)^2$$

Decompose total sum of squares (SST) into diff sources of variation:

- Between samples (SSTrt)
- Within sample (SSE)

$$\sum_i \sum_j (Y_{ij} - \bar{Y}_{..})^2 = \sum_i n_i (Y_{i.} - \bar{Y}_{..})^2 + \sum_{ij} (Y_{ij} - \bar{Y}_{i.})^2$$

# One-Way ANOVA Table

Source of Variation	df	Sum of Squares	Mean Squares
Treatment	I-1	SSTrt	SSTrt/(I-1)
Error	N-I	SSE	SSE/N-I
Total	N-1	SST	

A test statistic for  $H_o$  may be constructed based on the ratio

$$F = MSTrt/MSE$$

which, under  $H_o$  and model assumptions, has an  $F_{I-1, N-I}$  distribution, where  $N = \sum_i n_i$ .

# Implementation

R: `aov()` or `glm()`

SAS: PROC ANOVA, PROC GLM, and PROC MIXED.

```
> anov1 <- aov(Y~drug)
```

```
> summary(anov1)
```

	Df	SS	MSq	F Value	Pr(F)
drug	2	261.8	130.9	3.16	0.072
Residuals	15	621.3	41.4		

If  $\bar{Y}_{i.}$  has a normal distribution with mean  $\mu_i$  and variance  $\sigma^2/n_i$ ,

$$\frac{n_i(\bar{Y}_{i.} - \mu_i)}{\sqrt{MSE}}$$

has a t-distribution with N-I degrees of freedom. This result may be used to construct confidence interval for  $\mu_i$  or the difference between two means  $\mu_i - \mu_j$ .

**For the latter:**

a  $100(1 - \alpha)\%$  confidence interval is given by

$$D_{12} \pm t_{\alpha/2, N-I} \sqrt{MSE(1/n_i + 1/n_j)}$$

$$D_{ij} = \bar{Y}_{i.} - \bar{Y}_{j.}$$



- Suppose  $H_0$  is rejected,

$$H_0 : \mu_1 = \cdots = \mu_I$$

Interested in determining which means are different from which other ones.

If there are  $g > 2$  comparisons, the probability that at least one interval not including the true difference is no longer  $\alpha$ .

Assuming independence, the probability that at least one of the  $k$  comparisons will reject a true null hypothesis  $= 1 - (1 - \alpha)^k$

$k$	1	2	3	4	5	...	10
$\alpha_F$	0.05	0.10	0.14	0.19	0.23	...	0.40

For  $k = 10$  comparisons, there is a 40% chance that we will reject erroneously at least one true null hypothesis!

Goal: construct simultaneous confidence intervals, such that the joint or simultaneous level is at least the desired level,  $1 - \alpha$

## *Bonferroni Method*

Given  $g$  pairs of comparisons, the Bonferroni method constructs confidence intervals, each at level  $\alpha' = \alpha/g$ .

$$D_{ij} \pm t_{\alpha'/2, N-I} \sqrt{MSE(1/n_i + 1/n_j)}$$

Then the coverage probability of the joint or simultaneous confidence intervals is at least  $1 - \alpha$ .

## *Tukey Method*

$$D_{ij} \pm Q_{I, N-I}^{\alpha} \sqrt{MSE(1/n_i + 1/n_j)}$$

where  $Q_{I, N-I}^{\alpha}$  is the critical point of a Studentized range distribution with  $I$  means and  $N-I$  error degrees of freedom.

## *Scheffe Intervals*

A procedure that results in wider intervals than the Tukey intervals, but with correct coverage, is given by

$$D_{ij} \pm \sqrt{(I - 1)F_{\alpha, I, N-I}} \sqrt{MSE(1/n_i + 1/n_j)}$$

## *Fisher's Least Significant Difference*

A procedure that is often used for pre-defined comparisons, is

$$D_{ij} \pm F_{\alpha, I, N-I} \sqrt{MSE(1/n_i + 1/n_j)}$$

This procedure does not control the experiment-wise error rate, and results in narrow confidence intervals.

## *Dunnnett's Procedure*

When interest lies in comparing I-1 groups against a reference group:

$$D_{ij} \pm d_{I, N-I}^{\alpha} \sqrt{MSE(1/n_i + 1/n_j)}$$

Reading Assignment. For p-values:

```
help(p.adjust)
```

```
p.adjust(p, method = p.adjust.methods)
```

```
p.adjust.methods
```

```
# c("holm", "hochberg", "hommel", "bonferroni",... "fdr", "none")
```

```
help(pairwise.t.test)
```

# Departures From Assumptions


## *Non-normality*

- Validity of the p-values suspect in small samples.
- For large samples, the F-test is generally Robust
- Accompanying loss in efficiency may be substantial
- Confidence intervals will not be accurate

## Detection:

- Residual analysis: qqnorm, histograms, etc.

- `hist(resid(anov1));`
- `qqnorm(resid(anov1))`



## Measures against *Non-normality*:

- Transformations: Box-Cox

$$y(\lambda) = \begin{cases} \frac{y^\lambda - 1}{\lambda}, & \text{if } \lambda \neq 0; \\ \log y, & \text{if } \lambda = 0. \end{cases}$$

Alternatively, one may use nonparametric or robust procedures.



## *The Kruskal-Wallis test*

- A generalization of the Wilcoxon rank-sum test, when there are more than two groups.
- Based on the joint ranks of the observations (i.e., ranked from 1 to  $N = \sum_{i=1}^I n_i$ )
- Let  $R_{i\cdot}$  = mean of ranks for i'th group
- $R_{\cdot\cdot}$  be the overall mean rank.
- Then assuming no ties:

$$T_{KW} = \frac{12}{N(N+1)} \sum_{i=1}^I n_i (\bar{R}_{i\cdot} - R_{\cdot\cdot})^2$$

which under  $H_0 : \mu_1 = \dots = \mu_I$  has an approximate  $\chi^2_{I-1}$  distribution.

## Remarks:

- Approximation is good provided  $n_i > 5$
- If there are ties, appropriate correction factors must be used. (Reading Assignment)
- Kruskal-Wallis test assumes ordinal or numeric data
- Also assumes the shapes of the I distributions are the same.

One also may perform multiple comparisons using the following:

$$\bar{R}_i - \bar{R}_k \pm Z_{1-\alpha/2g} \left[ \frac{N(N+1)}{12} (1/n_i + 1/n_k) \right]^{1/2}$$

```
> kruskal.test(Y,drug)
```

Kruskal-Wallis rank sum test

data: Y and drug

Kruskal-Wallis chi-square = 7.9476, df = 2,  
p-value = 0.0188

alternative hypothesis: two.sided

## Departures From Assumptions

### *Unequal Variances*

- p-values may not be reliable.

effect is more serious if the large  $\sigma_i$  is associated with the smaller  $n_i$ 's. This typically leads to more frequent false rejections.

### Test for homogeneity of variances:

- Bartlett's test
- Levene's test
- Box's test
- Hartley's max test

# Bartlett's test

$$T = c^{-1}(\nu \ln(\hat{\sigma}^2) - \sum_i \nu_i \ln(\hat{\sigma}_i^2))$$

where  $\nu_i = n_i - 1$ ,  $\nu = \sum_i \nu_i$ , and

$$c = 1 + \frac{1}{3(I-1)}(\sum_i \nu_i^{-1} - \nu^{-1})$$

and  $\hat{\sigma}_i$  and  $\hat{\sigma}$  are the i'th sample and pooled variances. The test rejects when  $T > \chi_{I-1}^2$ .

The test is highly dependent on normality assumption.

# Two-Way ANOVA

In many applications, one-way ANOVA may not be adequate.

Examples: Data on blood pressure reductions for patients receiving 3 different drugs (cont'd)

Male

Drug 1: 11, 15, 11,

Drug 2: 8, 7, 8

Drug 3: 7, 9, 11

Female:

Drug 1: 10, 12, 37

Drug 2: 10, 12, 11

Drug 3: 9, 4, 2

# Two-Way ANOVA

A second variable included in a model to:

- Improve precision
- Reduce dependence within the levels of a factor of interest
- Reduce bias arising as a result of confounding

When the stratification variable is numeric, Analysis of Covariance (ANCOVA).

• When the variable is a factor with two or more levels, two-way ANOVA.

# Two-Way ANOVA

ANOVA model is given by:

$$Y_{ijk} = \mu_{ij} + \epsilon_{ijk}$$

where  $i = 1, \dots, I, j = 1, \dots, J, k = 1, \dots, n_{ij}$ ,  
and  $\epsilon_{ijk}$  are typically assumed to be i.i.d.  $N(0, \sigma^2)$ .

OLS estimator:

$$\hat{\mu}_{ij} = \bar{Y}_{ij}.$$

It is often more convenient to use the following  
alternative formulation

$$Y_{ijk} = \mu + \alpha_i + \beta_j + \gamma_{ij} + \epsilon_{ijk}$$



When the design is balanced, i.e., all  $n_{ij} = n$ , the least squares estimators of the unknown parameters are given as follows:

$$\hat{\mu} = \bar{Y}_{...}$$

$$\hat{\alpha}_i = \bar{Y}_{i..} - \bar{Y}_{...}$$

$$\hat{\beta}_j = \bar{Y}_{.j.} - \bar{Y}_{...}$$

$$\hat{\gamma}_{ij} = \bar{Y}_{ij.} - \bar{Y}_{i..} - \bar{Y}_{.j.} + \bar{Y}_{...}$$

Decomposition of SST for balanced 2-way designs:

$$SSA = nJ \sum_{i=1}^I (\bar{Y}_{i..} - \bar{Y}_{...})^2$$

$$SSB = nJ \sum_{j=1}^J (\bar{Y}_{.j.} - \bar{Y}_{...})^2$$

$$SSAB = n \sum_{i=1}^I \sum_{j=1}^J (\bar{Y}_{ij.} - \bar{Y}_{i..} - \bar{Y}_{.j.} + \bar{Y}_{...})^2$$

$$SSE = \sum_{ijk} (Y_{ijk} - \hat{Y}_{ij.})^2$$

*Two-Way ANOVA Table: Balanced Design*

Source	df	SS	MS
A	I-1	SSA	$MSA=SSA/(I-1)$
B	J-1	SSB	$MSB=SSB/(J-1)$
AB	$(I-1)(J-1)$	SSAB	$MSAB/(I-1)(J-1)$
Error	$IJ(n-1)$	SSE	$SSE/IJ(n-1)$
Total	$IJN-1$	SST	

hypothesis of no treatment effect,

$$H_0 : \alpha_1 = \cdots = \alpha_I$$

the normal-model test statistic is given by

$$F = \frac{MSA}{MSE}$$

which under  $H_0$  has an  $F_{I-1, IJ(n-1)}$  distribution.

When there is no significant interaction, it is often advisable to work with the reduced model,

$$Y_{ijk} = \mu + \alpha_i + \beta_j + \epsilon_{ijk}$$

Advantages of additive model formulation:

- More error degrees of freedom is obtained, giving more powerful F tests for the main effects.
- Estimation of main effect parameters straightforward even when the design is unbalanced or some cells are empty .

$$\hat{\mu}_{ij} = \hat{\mu} + \hat{\alpha}_i + \hat{\beta}_j$$


so that the i'th marginal mean is estimated by

$$\hat{\mu}_{i.} = \frac{\sum_{j=1}^J \hat{\mu}_{ij}}{J}$$


# When the interaction term is significant:

- Evaluate the nature and strength of the interaction.


**No Interaction**



**Quantitative Interaction**




**Qualitative Interaction**



When the interaction term is significant:

- Evaluate the nature and strength of the interaction.
  - Commonly used test to determine whether the interaction qualitative or quantitative: Gail-Simon test  
[Biometrics. Vol. 41 No. 2 (June 1985): 361-372 ]
  - Plot using `interaction.plot(block,trt,Y)`



```
> fit2way <- aov(Y~drug*sex)
```

```
> summary(fit2way)
```

	Df	SSq	Mean Sq	F Value	Pr(F)
drug	2	261.78	130.89	3.14	0.08
sex	1	22.22	22.22	0.53	0.48
drug:sex	2	99.11	49.56	1.19	0.34
Residuals	12	500.0	41.67		

# The Friedman rank-sum test

- Assumes a randomized block design without replication

$$Y_{ij} = \mu + \alpha_i + \beta_j + \epsilon_{ij}$$

and the null hypothesis of interest

$$H_0 : \alpha_1 = \cdots = \alpha_I$$

Within each block (ie.,  $j = 1, \dots, J$ ), rank the observations separately from 1 to  $I$ . Let  $\bar{R}_{i.}$  be the mean rank for the observations in the  $i$ 'th group. Then under  $H_0$ ,  $\bar{R}_{1.} \approx \cdots \approx \bar{R}_{I.}$

$$F = \frac{12J}{I(I+1)} \sum_{i=1}^I (\bar{R}_{i.} - \bar{R}_{..})^2$$

which, under  $H_0$ , is approximately  $\chi_{I-1}^2$ .



Implementation:

```
friedman.test(Y,groups,blocks)
```

SAS: PROC FREQ.

```
> tapply(Y,list(sex,drug),mean)
```

	D1	D2	D3
F	19.7	11.0	5
M	12.3	7.7	9

```
> Ymean <- c(19.7,12.3,11,7.7,5,9)
```

```
> Drug <-rep(c("D1","D2","D3"),c(2,2,2))
```

```
> Sex <-c("F","M","F","M","F","M")
```

```
> Drug <-factor(Drug)
```

```
> Sex <-factor(Sex)
```

```
> friedman.test(Ymean,Drug,Sex)
```

Friedman rank sum test

data: Ymean and Drug and Sex

Friedman chi-square = 3, df = 2, p-value = 0.2231

alternative hypothesis: two.sided

Other tests in PROC FREQ

– The Van Elteren test

## Example

Data on **Blood Pressure** reduction (Y),  
**Baseline Blood Pressure (Base)**  
and Treatment (trt)

ID	Y	Base	trt
1	7.1	61	Drug
2	6.6	56	Drug
3	7.8	58	Drug
4	6.8	68	Drug
5	9.4	64	Drug
6	9.7	57	Drug
7	8.5	55	Drug
8	9.9	59	Drug
9	6.1	51	Drug
10	8.0	60	Drug
11	8.8	88	Placebo
12	8.5	85	Placebo
13	8.1	81	Placebo
14	8.9	89	Placebo
15	8.7	87	Placebo
16	8.4	84	Placebo
17	8.1	81	Placebo
18	7.8	78	Placebo
8.1	8.1	81	Placebo
20	8.5	85	Placebo

One-Way ANOVA:

```
> summary(aov(Y ~ trt))
```

	Df	SS	MeanSq	F	Pr(F)
trt	1	0.42	0.42	0.60	<b>0.450</b>
Resid	18	12.68	0.70		

	<u>Base Mean</u>	<u>Y Mean</u>
Drug	59.7	8.07
Placebo	83.6	8.34

# Analysis of Covariance

## ANCOVA

**Example:** Subjects randomized to Drug or Placebo.

Data on **Blood Pressure** reduction (Y) after 4 weeks of treatment,

**Baseline Blood Pressure (Base)**

**Ho: No Difference in Mean BP Reduction (Y) for Drug & Placebo**

ID	Y	Base	trt
1	7.1	61	Drug
2	6.6	56	Drug
3	7.8	58	Drug
4	6.8	68	Drug
5	9.4	64	Drug
6	9.7	57	Drug
7	8.5	55	Drug
8	9.9	59	Drug
9	6.1	51	Drug
10	8.0	60	Drug
11	8.8	88	Placebo
12	8.5	85	Placebo
13	8.1	81	Placebo
14	8.9	89	Placebo
15	8.7	87	Placebo
16	8.4	84	Placebo
17	8.1	81	Placebo
18	7.8	78	Placebo
19	8.1	81	Placebo
20	8.5	85	Placebo

One-Way ANOVA:

```
> summary(aov(Y ~ trt))
```

	Df	SS	MeanSq	F	Pr(F)
trt	1	0.42	0.42	0.60	<b>0.450</b>
Resid	18	12.68	0.70		

	<u>Base Mean</u>	<u>Y Mean</u>
Drug	59.7	8.07
Placebo	83.6	8.34

Regression Effect

Regression to the Mean

Suppose  $X_{ij}$  is a covariate of interest, and consider the ANOCVA model

$$Y_{ij} = \mu_i + \beta X_{ij} + \epsilon_{ij}$$

Note that

$$\bar{Y}_{i.} \approx \hat{\mu}_i + \beta \bar{X}_{i.}$$

Thus, comparing  $\mu_i$  and  $\mu_k$  based on  $\bar{Y}_{i.} - \bar{Y}_{k.}$  would be inappropriate unless  $\bar{X}_{i.} = \bar{X}_{k.}$ . So, comparison is generally performed at a common value of  $X$ , say  $\bar{X}_{..}$ . For convenience, let

$$Y_{ij} = \mu_i + \beta(X_{ij} - \bar{X}_{..}) + \epsilon_{ij}$$

## Adjusted mean (a.k.a. LS Mean)

$$\hat{\mu}_i = \hat{Y}_{i.} - \hat{\beta}(\bar{X}_{i.} - \bar{X}_{..})$$

In the above

$$\hat{\beta} = \frac{\sum_{i=1}^I \sum_{j=1}^{n_i} (y_{ij} - \bar{Y}_{i.})(X_{ij} - \bar{X}_{i.})}{\sum_{i=1}^I \sum_{j=1}^{n_i} (X_{ij} - \bar{X}_{i.})^2}$$

$$\hat{\sigma}^2 = \frac{1}{N - I - 1} \sum_{ij} (Y_{ij} - \hat{\mu}_i - \hat{\beta}(\bar{X}_{i.} - \bar{X}_{..}))^2$$

$$\text{var}(\hat{\beta}) = \frac{\sigma^2}{\sum_{i=1}^I \sum_{j=1}^{n_i} (X_{ij} - \bar{X}_{i.})^2}$$

One-Way ANOVA:

```
> summary(aov(Y ~ trt))
```

	Df	SS	MeanSq	F	Pr(F)
trt	1	0.42	0.42	0.60	<b>0.450</b>
Resid	18	12.68	0.70		

## ANCOVA

```
> summary(aov(Y ~ Base+trt))
```

	Df	SS	MeanSq	F	Pr(F)
Base	1	2.40	2.40	5.9	0.026
trt	1	3.81	3.81	9.41	<b>0.007</b>
Resid	17	6.89	0.41		

	<u>Base</u>	<u>Y</u>	<u>LSM</u>
Drug	59.7	8.07	9.3
Placebo	83.6	8.34	7.1

## Nonparallel Regression Lines

Suppose now that

$$Y_{ij} = \mu_i + \beta_i(X_{ij} - \bar{X}_{..}) + \epsilon_{ij}$$

The above arises when the marginal mean differences are different for different values of  $X_{ij}$ .

- In the blood pressure example, patients may respond differently to different drugs depending on the values of their baseline blood pressure.



When the lines are not parallel, different lines have to be fitted for each  $i$ .

$$\hat{\beta}_i = \frac{\sum_{j=1}^{n_i} (y_{ij} - \bar{Y}_{i.})(X_{ij} - \bar{X}_{i.})}{\sum_{j=1}^{n_i} (X_{ij} - \bar{X}_{i.})^2}$$

giving

$$\hat{\mu}_i = \hat{Y}_{i.} - \hat{\beta}_i(\bar{X}_{i.} - \bar{X}_{..})$$

A test for parallelism may be performed by testing for the significance of treatment-by-covariate interaction

$$H_0 : \beta_1 = \cdots \beta_I$$

The test statistic is given by

$$\frac{\sum_{i=1}^I (\hat{\beta}_i - \hat{\beta})^2 \sum_j (X_{ij} - \bar{X}_{i.})^2}{(I - 1)\hat{\sigma}^2}$$

which under  $H_0$  has an  $F_{I-1, N-2I}$  distribution.

In the above

$$\hat{\beta} = \frac{\sum_{i=1}^I \sum_{j=1}^{n_i} (Y_{ij} - \bar{Y}_{i.})(X_{ij} - \bar{X}_{i.})}{\sum_{i=1}^I \sum_{j=1}^{n_i} (X_{ij} - \bar{X}_{i.})^2}$$

## Test for Parallelism

```
> summary(aov(Y ~ Base*trt))
```

	Df	SS	MeanSq	F	Pr(F)
Base	1	2.401	2.40	5.590	0.031
trt	1	3.814	3.81	8.88	0.009
Base:trt	1	0.017	0.017	0.04	<b>0.840</b>

When  $H_0$  is rejected, inference about the marginal mean differences must be performed for each  $X = x$

Remarks:

For non-normal data, use rank-based ANCOVA:

- Iman and Conover: Ranks are substituted for Y and X, if both random
- Stephen and Jacobson: Transform only Y, if X is fixed (e.g.,  $X = \text{Age}$ ).

# Other ANOVA Models

**Example 1.** Study on effects of teaching methods on student performance. All 5 teachers in a given school (i.e., 5 different methods) included in a study, each assigned 10 students at random. At the end of a training period, scores on a standardized test recorded.

**Example 2.** In another school there are 100 teachers. 5 teachers chosen at random (i.e., 5 different methods), and each assigned 10 students at random. At the end of a training period, scores on a standardized test recorded.

NB: The first school corresponds to Fixed Effects ANOVA (Model I), since all the levels of the factor “Teacher” are in the study.

The levels of the factor “Teacher” in the second case are random.  
Corresponds to Random Effects ANOVA (Model II)

# One Way Random Effects ANOVA Model (Model II)

$$Y_{ij} = \mu_i + \epsilon_{ij}$$

where  $\mu_i$  are iid  $N(\mu, \sigma_A^2)$ ,  $\epsilon_{ij}$  are also iid  $N(0, \sigma_e)$ , and independent of  $\mu_i$ . Note that if all teachers teach the same way,  $\mu_i = \mu$ , and hence  $\sigma_A^2 = 0$ .

A test for treatment difference may then be formulated in term sof

$$H_0 : \sigma_A^2 = 0$$

vs

$$H_1 : \sigma_A^2 > 0$$

Total sum of squares (SST) decomposed:

- Sum of squares due to treatment (SSA)+
- Error sum of squares (SSE), where

$$SSA = \sum_i n_i (\bar{Y}_{i.} - \bar{Y}_{..})^2$$

$$SSE = \sum_i \sum_j (Y_{ij} - \bar{Y}_{i.})^2$$

Assuming all  $n_i = n$ , it can also be shown that,

$$E[MSA] = E[SSA/(I - 1)] = n\sigma_A^2 + \sigma_e^2.$$

$$E(MSE) = \sigma_e^2.$$



To test

$$H_0 : \sigma_A^2 = 0$$

vs

$$H_1 : \sigma_A^2 > 0$$

$$F = \frac{MSA}{MSE}$$

which under  $H_0$  has an  $F_{I-1, N-I}$  distribution

Remark: In the One-way case, the test similar  
to that of Fixed Effects model

Reading assignment: Confidence intervals for  $\sigma_A^2$  and  $\frac{\sigma_A^2}{\sigma_A^2 + \sigma_e^2}$

## Two-Factor Models: Model II

$$Y_{ijk} = \mu + a_i + b_j + (ab)_{ij} + \epsilon_{ijk}$$

where  $i = 1, \dots, I; j = 1, \dots, J; k = 1, \dots, n_{ij};$   
 $a_i, b_j, (ab)_{ij}, \epsilon_{ijk}$  are mutually independent normal random variables, with mean 0, and respective variances:  $\sigma_A^2, \sigma_B^2, \sigma_{AB}^2, \sigma_e^2.$

When the design is balanced, we have

$$SST = SSA + SSB + SSAB + SSE$$

where

$$SSA = nJ \sum_i (\bar{Y}_{i..} - \bar{Y}_{..})^2$$

$$SSB = nI \sum_j (\bar{Y}_{.j.} - \bar{Y}_{..})^2$$

$$SSAB = n \sum_{ij} (\bar{Y}_{ij.} - \bar{Y}_{i..} - \bar{Y}_{.j.} + \bar{Y}_{..})^2$$

$$SSE = \sum_{ijk} (Y_{ijk} - \bar{Y}_{ij.})^2$$

and

$$SST = \sum_{ijk} (Y_{ijk} - \bar{Y}_{..})^2$$

$$E(MSA) = \sigma_e^2 + n\sigma_{AB}^2 + nJ\sigma_A^2$$

$$E(MSB) = \sigma_e^2 + n\sigma_{AB}^2 + NI\sigma_B^2$$

$$E(MSAB) = \sigma_e^2 + n\sigma_{AB}^2$$

and

$$E(MSE) = \sigma_e^2$$

*Two-Way Random Effects Model ANOVA Table*

Source	df	SS	MS	EMS
A	I-1	SSA	SSA/(I-1)	$\sigma_e^2 + n\sigma_{AB}^2 + nJ\sigma_A^2$
B	J-1	SSB	SSB/(J-1)	$\sigma_e^2 + n\sigma_{AB}^2 + nI\sigma_B^2$
AB	(I-1)(J-1)	SSAB	SSAB/(I-1)(J-1)	$\sigma_e^2 + n\sigma_{AB}^2$
Error	(n-1)IJ	SSE	SSE / (n-1)IJ	$\sigma_e^2$
TOTAL	N-1	SST		

# Mixed Effects Models: Model III

Example: Suppose three treatments are to be compared.

- 5 hospitals selected at random from a district of 100 hospitals
- 5 patients are randomly assigned to each treatment in each hospital
- The factor "treatment" is fixed, since all the levels are included in the study.
- "Hospital" is random, since the levels are a random sample.

# Two-way Mixed Effects Model

$$Y_{ijk} = \mu + \alpha_i + b_j + (\alpha b)_{ij} + \epsilon_{ijk}$$

where  $\mu$  and  $\alpha_i$  are constant,

$$b_j \sim N(\mu, \sigma_b^2)$$

$$(\alpha b)_{ij} \sim N(0, \frac{(I-1)}{I} \sigma_{AB}^2),$$

$\epsilon_{ijk}$  is  $N(0, \sigma_e^2)$ , and all the random quantities are mutually independent.

*Two -Way Mixed Effects ANOVA Table*

Source	df	SS	MS	EMS
A (Fixed)	I-1	SSA	SSA/(I-1)	$\sigma_e^2 + \frac{nJ}{J-1} \sum_i \alpha_i^2 + n\sigma_{AB}^2$
B (Random)	J-1	SSB	SSB/(J-1)	$\sigma_e^2 + nI\sigma_B^2$
AB (Random)	(I-1)(J-1)	SSAB	SSAB/(I-1)(J-1)	$\sigma_e^2 + n\sigma_{AB}^2$
Error (Random)	(n-1)IJ	SSE	SSE / (n-1)IJ	$\sigma_e^2$
TOTAL	N-1	SST		

Two -Way Mixed Effects ANOVA Table: Balanced Design

Source	df	SS	MS	EMS
A (Fixed)	I-1	SSA	SSA/(I-1)	$\sigma_e^2 + \frac{nJ}{I-1} \sum_i \alpha_i^2 + n\sigma_{AB}^2$
B (Random)	J-1	SSB	SSB/(J-1)	$\sigma_e^2 + nI\sigma_B^2$
AB (Random)	(I-1)(J-1)	SSAB	SSAB/((I-1)(J-1))	$\sigma_e^2 + n\sigma_{AB}^2$
Error (Random)	(n-1)IJ	SSE	SSE / (n-1)IJ	$\sigma_e^2$
TOTAL	N-1	SST		

Inference about the fixed effect (A)

$$H_0 : \alpha_i = 0$$

$$F = \frac{MSA}{MSAB}$$

which under  $H_0$  has an  $F_{I-1, (I-1)(J-1)}$  distribution

If the interaction term is not significant, then an appropriate test statistic, based on the reduced model, is

$$F = \frac{MSA}{MSAB + MSE}$$

Null distribution?



Inference about the random effect (B)

$$H_0 : \beta_j = 0$$

$$F = \frac{MSB}{MSE}$$

which under  $H_o$  has an  $F_{I-1,(n-1)IJ}$  distribution

Two -Way Mixed Effects ANOVA Table: Balanced Design

Source	df	SS	MS	EMS
A (Fixed)	I-1	SSA	SSA/(I-1)	$\sigma_e^2 + \frac{nJ}{I-1} \sum_i \alpha_i^2 + n\sigma_{AB}^2$
B (Random)	J-1	SSB	SSB/(J-1)	$\sigma_e^2 + nI\sigma_B^2$
AB (Random)	(I-1)(J-1)	SSAB	SSAB/((I-1)(J-1))	$\sigma_e^2 + n\sigma_{AB}^2$
Error (Random)	(n-1)IJ	SSE	SSE / (n-1)IJ	$\sigma_e^2$
TOTAL	N-1	SST		

Example. Consider a study comparing 3 teaching methods.

- A random sample of 5 schools selected
- From each school 3 teachers randomly chosen.
  - Each teacher was then assigned a teaching method at random and asked to apply it in their class of about 20 students each.
- The scores ( $Y_{ij}$ ) of each student were then recorded at the end of the semester.

In this example, each level of the factor "teacher" occurs with only one level of "school", and each of the 15 levels is meaningful only given the level of "school". The factor "teacher" is said to be *nested* within "school".

# Two-Way Nested Designs

When both factors are random,

$$Y_{ijk} = \mu + a_i + b_{j(i)} + \epsilon_{ijk}$$

where  $b_{j(i)}$  denotes the effect of B at the  $j$ 'th level, when A is at the  $i$ 'th level. Further  $a_i$ ,  $b_{j(i)}$  and  $\epsilon_{ijk}$  are mutually independent normal

random variables, with mean 0 and, respective variances:

$$\sigma_A^2, \sigma_{B(A)}^2 \text{ and } \sigma_e^2$$

For the balanced case, the sums of squares are given by:

$$SSA = Jn \sum_i (\bar{Y}_{i..} - \bar{Y}_{...})^2$$

$$SSB(A) = n \sum_{ij} (\bar{Y}_{ij.} - \bar{Y}_{i..})^2$$

$$SSE = \sum_{ijk} (\bar{Y}_{ijk} - \bar{Y}_{ij.})^2$$

*Two -Way Nested Random Effects ANOVA Table*

Source	df	SS	MS	EMS
A (Random)	I-1	SSA	SSA/(I-1)	$\sigma_e^2 + nJ\sigma_A^2 + n\sigma_{B(A)}^2$
B(A) (Random)	I(J-1)	SSB(A)	SSB(A)/I(J-1)	$\sigma_e^2 + n\sigma_{B(A)}^2$
Error (Random)	(n-1)IJ	SSE	SSE / (n-1)IJ	$\sigma_e^2$
TOTAL	N-1	SST		

When A is fixed and B is random, and B(A):

Source	df	SS	MS	EMS
A (Fixed)	I-1	SSA	SSA/(I-1)	$\sigma_e^2 + nJ \frac{J_n}{I-1} \sum_i \alpha_i^2$
B(A) (Random)	I(J-1)	SSB(A)	SSB(A)/I(J-1)	$\sigma_e^2 + \frac{n}{I(n-1)} \sum_{ij} \beta_{j(i)}^2$
Error (Random)	(n-1)IJ	SSE	SSE / (n-1)IJ	$\sigma_e^2$
TOTAL	N-1	SST		

# Repeated Measures Design

Example. Consider a clinical trial comparing three treatment groups. Subjects were randomized to each treatment, and measurements were taken at weekly.

Observation taken over time on the same subject may be correlated.

- The usual ANOVA will not be applicable to this case.

## Repeated Measures Design

Let  $Y_{ijk}$  denote the measurement on the  $k$ 'th subject, assigned to treatment  $i$ , and taken at time  $j$ .

$$Y_{ijk} = \mu + \alpha_i + \tau_j + (\alpha\tau)_{ij} + S(\alpha)_{k(i)} + \epsilon_{ijk}$$

where  $\alpha_i$  is the  $i$ 'th treatment effect,  $\tau$  is time effect, and  $S(\alpha)$  stands for subject nested in treatment.

Since the error terms may be correlated, several correlation structures may be possible:

- Compound symmetry (i.e., equal correlations)

$$\text{Corr}(Y_{ijk}, Y_{ilk}) = \rho, \quad \forall j \neq l$$

- AR(1)
- Unstructured

The following is a decomposition of the Total Sum of Squares (SST)

$$SSTreatment = J \sum_i n_i (\bar{Y}_{i..} - \bar{Y}_{...})^2$$

$$SSTime = n_+ \sum_j (\bar{Y}_{.j.} - \bar{Y}_{...})^2$$

$$SSTreat * Time = \sum_{i,j} n_{ij} (\bar{Y}_{ij.} - \bar{Y}_{i..} - \bar{Y}_{.j.} + \bar{Y}_{...})^2$$

$$SSS(Treat) = J \sum_{i,k} n_{i.} (\bar{Y}_{i.k} - \bar{Y}_{i..})^2$$

$$SSE = \sum_{i,j,k} (Y_{ijk} - \bar{Y}_{i.k} - \bar{Y}_{ij.} + \bar{Y}_{i..})^2$$

$$SST = \sum_{i,j,k} (Y_{ijk} - \bar{Y}_{i..})^2$$



*Repeated Measures ANOVA Table*

Source	df	SS	F Statistic
Treatment	I-1	SS Treat	$\frac{MSTreat}{MS\ S(Treat)}$
Time	J-1	SS Time	$\frac{MSTime}{MSE}$
Treat*Time	(I-1)(J-1)	SS Time*Time	$\frac{MSTreat*Time}{MSE}$
S (Treat)	$\sum_i (n_i - 1) = n_+ - I$	SS S(Treat)	$\frac{MSS(Treat)}{MSE}$
Error	$(\sum_i n_i - J)(J - 1)$	SSE	
Total	SST		

## Remarks:

- $\frac{MSTime}{MSE}$  and  $\frac{MSTreat*Time}{MSE}$  may not have an F distribution with the usual degrees of freedom. Indeed, actual significance may be less strong than given by table.

Under certain conditions (Huynh & Feldt ), the distributions are F (e.g., when the correlation structure is independent or exchangeable or AR(1)).

- More generally, models that take into account the correlation structure must be used (SAS PROC MIXED).

### **Example: Repeated measures**

Subjects randomized to either Group 1, 2 or 3.

For each subject, response measured at Time 1, 2 and 3,  
following randomization and treatment.

ID Group Time Y

1 1 1 15

1 1 2 29

1 1 3 25

2 1 1 11

2 1 2 28

2 1 3 27

3 2 1 14

3 2 2 12

3 2 3 16

4 2 1 11

4 2 2 10

4 2 3 13

5 3 1 21

5 3 2 22

5 3 3 19

6 3 1 14

6 3 2 18

6 3 3 16

7 3 1 13

7 3 2 10

7 3 3 11

```

proc glm data=repeat;
class ID Group Time;
model Y=Group ID(Group)Time group*time/ss3;
test h=group e=id(group);
run;

```

Source	DF	SS3	MS	F	Pr > F
Group	2	303	152	50.50	<.0001
ID(Group)	4	143	35.7	11.90	0.0019
Time	2	105	52.6	17.53	0.0012
Group*Time	4	211.6	52.9	17.63	0.0005

Tests of Hypotheses Using the Type III MS for ID(Group) as an Error Term

Source	DF	Type III SS	MS	F Value	Pr > F
Group	2	303	152	4.24	0.1027

## **Reading Assignment :**

SAS' PROC GLM gives Type I - Type III SS.

Example: Model  $Y = A + B + A * B$

Type I SS: Order-dependent (hierarchical, sequential). Each effect is adjusted for all other effects that appear earlier (to the left) in the model, but not for any effects that appear later in the model.

Type II SS are the reduction in the  $SSE$  due to adding the effect to a model that contains all other effects except effects that contain the effect being tested

Types III SS are each adjusted for all other effects in the model, regardless of order.

```
proc glm data=repeat;
class ID Group Time;
model Y=Group ID(Group)Time group*time/ss1;
test h=group e=id(group);
run;
```

Source	DF	Type I SS	Mean Square	F Value	Pr > F
Group	2	302.9761905	151.4880952	50.50	<.0001
ID(Group)	4	142.8333333	35.7083333	11.90	0.0019
Time	2	80.3809524	40.1904762	13.40	0.0028
Group*Time	4	211.6190476	52.9047619	17.63	0.0005

#### Tests of Hypotheses Using the Type I MS for ID(Group) as an Error Term

Source	DF	Type I SS	Mean Square	F Value	Pr > F
Group	2	302.9761905	151.4880952	4.24	0.1027

Reading assignment:

Compare the above results with the results obtained using the R function

**aov(Y ~ Group\*Time+Error(ID))**

```

proc mixed data=repeat;
class ID Group Time;
model Y=Group Time group*time;
repeated/type=cs subject=ID;
run;

```

### Type 3 Tests of Fixed Effects

	Num	Den		
Effect	DF	DF	F Value	Pr > F
Group	2	4	4.24	0.1027
Time	2	8	17.53	0.0012
Group*Time	4	8	17.63	0.0005

## Problem Set

Reading Assignment: Ramsey and Shafer; Chapters 5, 6, 13

1. Consider the Duodenal Ulcer data given in Problem 25, Chapter 5.
  - a) Using an appropriate ANOVA model, determine whether there is a significant difference among the group means. Use both an F test and simultaneous confidence interval procedures
  - b) Assess the assumptions of the ANOVA model.
  - c) Compare the results to those obtained using a non-parametric procedure.
  
- 2) Consider the IQ scores data of Display 13.24, problem 19, Chapter 13.
  - a) Do problem 19
  - b) Assess the validity of all assumptions.